This trial is enrolling 16 participants previously treated with an experimental bladder drug to assess its long-term safety and tolerability. The drug, EG110A, is being studied for its effects on bladder function in people with spinal cord injury, with the aim of reducing involuntary bladder muscle contractions. If included, participants will continue follow-up after completion or early discontinuation of a prior EG110A clinical study (NCT06596291). Final testing of long-term safety will be performed after 5 years.
Traumatic
Type
Details
- Participants will continue follow-up after completion or early discontinuation of a prior EG110A clinical study (NCT06596291). - EG110A is an investigational drug being studied for its effects on bladder function in people with spinal cord injury, with the aim of reducing involuntary bladder muscle contractions. - Final testing of long-term safety will be performed after 5 years.
Main benefits
General health
Additional benefits
Bladder health/function
Mental health and psychosocial factors
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more